We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Catalent's (CTLT) Latest Partnership to Boost Clinical Trials
Read MoreHide Full Article
Catalent, Inc. (CTLT - Free Report) recently entered a strategic partnership with Siren Biotechnology. The tie-up aims to support the development and manufacturing of Siren Biotechnology’s adeno-associated viral (AAV) immuno-gene therapies.
The latest partnership is expected to be a significant stepping stone for its Biologics business and solidify its foothold in the niche space.
Rational Behind the Collaboration
Under the partnership, Catalent will provide process development and cGMP (current good manufacturing practices) manufacturing of Siren Biotechnology’s AAV vector-based therapeutic candidates for use in clinical trials. Catalent will also support process optimization at its process and clinical development center in Baltimore, MD.
Per Catalent’s management, the partnership is expected to pave the path for the development and commercial manufacturing of safe and high-quality AAV gene therapies to provide life-saving treatments to cancer patients.
Siren Biotechnology’s management believes that the tie-up will result in a robust manufacturing process that will move its therapeutic programs into the clinic as quickly as possible.
Industry Prospects
Per a report by Grand View Research, the global adeno-associated virus vector manufacturing market was valued at $767.7 million in 2022 and is anticipated to expand at a CAGR of 22.5% between 2023 and 2030. Factors like the increase in the number of clinical trials and clinical trial evaluations of AAV vector-based therapies and technological advancements in gene therapies are likely to drive the market.
Given the market potential, the latest tie-up will likely provide a significant impetus to Catalent in the cell and gene therapy space.
Notable Development
This month, Catalent reported its third-quarter fiscal 2024 results, wherein it recorded a year-over-year improvement in its overall top-line and bottom-line results. Management also confirmed to witness continued momentum in the Biologics segment, which partially drove an increase in consolidated sequential revenues and adjusted EBITDA margin for the second consecutive quarter.
Price Performance
Shares of Catalent have gained 68.2% in the past year against the industry’s 10.1% decline. The S&P 500 has witnessed 26.5% growth in the said time frame.
Image Source: Zacks Investment Research
Zacks Rank & Key Picks
Currently, Catalent carries a Zacks Rank #3 (Hold).
DaVita, sporting a Zacks Rank #1 (Strong Buy) at present, has an estimated long-term growth rate of 13.6%. DVA’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 29.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.
DaVita’s shares have gained 41.9% compared with the industry’s 23.3% rise in the past year.
Veeva Systems, flaunting a Zacks Rank of 1 at present, has an estimated long-term growth rate of 24.1%. VEEV’s earnings surpassed estimates in each of the trailing four quarters, with the average being 8.5%.
Veeva Systems has gained 15.4% compared with the industry’s 47.8% rise in the past year.
Ecolab, carrying a Zacks Rank of 2 (Buy) at present, has an estimated long-term growth rate of 13.5%. ECL’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 1.3%.
Ecolab’s shares have rallied 34.4% against the industry’s 10.1% decline in the past year.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Catalent's (CTLT) Latest Partnership to Boost Clinical Trials
Catalent, Inc. (CTLT - Free Report) recently entered a strategic partnership with Siren Biotechnology. The tie-up aims to support the development and manufacturing of Siren Biotechnology’s adeno-associated viral (AAV) immuno-gene therapies.
The latest partnership is expected to be a significant stepping stone for its Biologics business and solidify its foothold in the niche space.
Rational Behind the Collaboration
Under the partnership, Catalent will provide process development and cGMP (current good manufacturing practices) manufacturing of Siren Biotechnology’s AAV vector-based therapeutic candidates for use in clinical trials. Catalent will also support process optimization at its process and clinical development center in Baltimore, MD.
Per Catalent’s management, the partnership is expected to pave the path for the development and commercial manufacturing of safe and high-quality AAV gene therapies to provide life-saving treatments to cancer patients.
Siren Biotechnology’s management believes that the tie-up will result in a robust manufacturing process that will move its therapeutic programs into the clinic as quickly as possible.
Industry Prospects
Per a report by Grand View Research, the global adeno-associated virus vector manufacturing market was valued at $767.7 million in 2022 and is anticipated to expand at a CAGR of 22.5% between 2023 and 2030. Factors like the increase in the number of clinical trials and clinical trial evaluations of AAV vector-based therapies and technological advancements in gene therapies are likely to drive the market.
Given the market potential, the latest tie-up will likely provide a significant impetus to Catalent in the cell and gene therapy space.
Notable Development
This month, Catalent reported its third-quarter fiscal 2024 results, wherein it recorded a year-over-year improvement in its overall top-line and bottom-line results. Management also confirmed to witness continued momentum in the Biologics segment, which partially drove an increase in consolidated sequential revenues and adjusted EBITDA margin for the second consecutive quarter.
Price Performance
Shares of Catalent have gained 68.2% in the past year against the industry’s 10.1% decline. The S&P 500 has witnessed 26.5% growth in the said time frame.
Image Source: Zacks Investment Research
Zacks Rank & Key Picks
Currently, Catalent carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are DaVita Inc. (DVA - Free Report) , Veeva Systems Inc. (VEEV - Free Report) and Ecolab Inc. (ECL - Free Report) .
DaVita, sporting a Zacks Rank #1 (Strong Buy) at present, has an estimated long-term growth rate of 13.6%. DVA’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 29.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.
DaVita’s shares have gained 41.9% compared with the industry’s 23.3% rise in the past year.
Veeva Systems, flaunting a Zacks Rank of 1 at present, has an estimated long-term growth rate of 24.1%. VEEV’s earnings surpassed estimates in each of the trailing four quarters, with the average being 8.5%.
Veeva Systems has gained 15.4% compared with the industry’s 47.8% rise in the past year.
Ecolab, carrying a Zacks Rank of 2 (Buy) at present, has an estimated long-term growth rate of 13.5%. ECL’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 1.3%.
Ecolab’s shares have rallied 34.4% against the industry’s 10.1% decline in the past year.